Baker Bros. Advisors reported a buy of 2,005,813 Kymera Therapeutics (NASDAQ:KYMR) shares in its February 17, 2026, SEC filing, an estimated $135.45 million trade based on quarterly average pricing. What happened According to a February 17, 2026 SEC filing, Baker Bros. increased its holding in Kymera Therapeutics (NASDAQ:KYMR) by 2,005,813 shares. The estimated trade value was $135.45 million, based on the average closing price during the fourth quarter of 2025. The fund’s quarter-end position value in K ...

WATERTOWN, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, will report fourth quarter and full year 2025 financial results on February 26, 2026. The Company will host a video conference call and webcast at 8:30 a.m. ET that day. To join the video call or view the livestreamed webcast, please register via this link, or visit “News and Events ...

On February 17, 2026, Rock Springs Capital Management disclosed a buy of 46,497 shares of Kymera Therapeutics (NASDAQ:KYMR), with the estimated transaction value at $3.14 million based on quarterly average pricing. What happened According to a Securities and Exchange Commission (SEC) filing dated February 17, 2026, Rock Springs Capital Management LP increased its stake in Kymera Therapeutics by 46,497 shares. The estimated transaction value for the quarter was $3.14 million, based on the average closing ...

Kymera Therapeutics Conference Call Summary Company Overview - **Company**: Kymera Therapeutics - **Focus**: Targeted protein degradation technology aimed at transforming treatment paradigms in immunology with oral drugs that deliver biologics-like efficacy [3][4] Key Industry Insights - **Market Potential**: The atopic dermatitis (AD) market is valued at approximately $10 billion, with a significant opportunity for expansion due to the presence of only 1-2 drugs in many Type II disease markets [8][10] - **Patient Population**: There are over 100 million patients with Type II diseases, with 40-50 million being moderate to severe cases, indicating a large unmet need [8][9] - **Market Dynamics**: Current yearly sales in the relevant drug markets are around $20-$25 billion, with expectations for market expansion by 5-10 times as new oral drugs are introduced [10][11] Product Development and Strategy - **Drug Profile**: KT-621 is positioned as a Type II drug with the potential to provide biologics-like efficacy in an oral format, which is preferred by patients due to convenience and psychological factors [16][17] - **Patient Preferences**: Most patients prefer oral medications over injections, which can be psychologically burdensome [16][17] - **Pediatric Focus**: There is a significant opportunity to serve pediatric patients who currently lack effective therapies, with the potential to alter the disease trajectory if treated early [18] Competitive Landscape - **Market Comparison**: There has not been an oral drug with biologics-like activity in the market, making KT-621 a unique offering. Comparisons are drawn to Otezla, which succeeded despite lower efficacy due to its oral format [19][20] - **Efficacy Expectations**: The company anticipates that KT-621 will outperform existing treatments like Dupixent based on early data, with expectations of a robust treatment effect in upcoming trials [33][40] Clinical Data and Development - **Phase 1b Study Results**: The study demonstrated a strong correlation between target degradation and improvements in multiple biomarkers associated with AD, suggesting a high probability of success in Phase II trials [31][34] - **Safety Profile**: The safety profile of KT-621 has been reported as clean, with no treatment-related adverse events in the healthy volunteer study [24][25] - **Future Studies**: The company is preparing for Phase II studies, focusing on selecting the right dose for Phase III trials while ensuring efficacy and safety [50] Biomarker Insights - **FeNO as a Biomarker**: FeNO levels were significantly reduced in asthma patients, indicating potential efficacy in asthma treatment as well [52][55] Pipeline Programs - **IRF5 Program**: The IRF5 program has genetic validation, which is rare in drug development. The company is confident in the drug's ability to degrade the target effectively and translate preclinical findings into clinical success [56][59] Conclusion - **Market Positioning**: Kymera Therapeutics is positioned to potentially become a significant player in the biotech space with its innovative approach to oral drug delivery and targeted protein degradation technology, addressing large unmet needs in immunology [11][12]

Core Insights - Kymera Therapeutics (KYMR) has initiated patient dosing in the phase IIb BREADTH study for KT-621, targeting moderate-to-severe eosinophilic asthma, with top-line data expected in late 2027 [1][6] - KT-621 is a first-in-class oral degrader of STAT6, which plays a crucial role in IL-4/IL-13 signaling and type II inflammation [1][3] - The study aims to address the significant unmet need for effective asthma treatments, as current options are limited to inhalers and injectable biologics [2][3] Study Details - The BREADTH study is a randomized, dose-ranging trial involving approximately 264 adults over 12 weeks, assessing three doses of KT-621 [4] - Primary endpoint is the change in forced expiratory volume in one second (FEV1) from baseline, with secondary endpoints focusing on additional efficacy, safety, tolerability, and quality of life [4] - Eligibility criteria include a blood eosinophil count of at least 300 cells/µL and pre-bronchodilator FEV1 between 40% and 80% of predicted normal [4] Market Performance - Over the past six months, Kymera Therapeutics' stock has increased by 68.9%, outperforming the industry growth of 22.7% [5] Additional Indications - KT-621 is also being evaluated for atopic dermatitis (AD), with positive phase Ib BroADen study results showing significant STAT6 degradation and reductions in disease-relevant biomarkers [9][10] - A concurrent phase IIb BROADEN2 study for AD is underway, expecting to report data by mid-2027 [11][12] - The dual focus on asthma and AD is intended to expedite KT-621's development and support dose selection for future phase III studies [12]

Core Insights - Kymera Therapeutics has initiated dosing in its BREADTH Phase 2b clinical trial for KT-621, targeting moderate to severe eosinophilic asthma, with data expected in late-2027 [1][2] - The company is also conducting the BROADEN2 Phase 2b trial for atopic dermatitis, with results anticipated by mid-2027 [1][3] - KT-621 is a first-in-class oral degrader of STAT6, aimed at treating Type 2 inflammatory diseases, showing promising results in earlier studies [4] Group 1: Clinical Trials - The BREADTH Phase 2b trial is a global, randomized, double-blind, placebo-controlled study involving approximately 264 adult patients over 12 weeks, focusing on the efficacy, safety, and tolerability of KT-621 [2] - The primary endpoint of the BREADTH trial is the change in forced expiratory volume in one second (FEV1) from baseline, with secondary endpoints assessing additional safety and quality of life measures [2] - The BROADEN2 trial is parallel to the BREADTH trial and is expected to accelerate the development of KT-621 for multiple Type 2 indications [3] Group 2: Product Information - KT-621 is designed to degrade STAT6, a key transcription factor in IL-4/IL-13 signaling, which drives Type 2 inflammation [4] - In Phase 1 studies, KT-621 demonstrated significant STAT6 degradation and reductions in Type 2 inflammatory biomarkers, along with improvements in clinical endpoints and patient-reported outcomes [4] - The drug has the potential to address a wide range of Type 2 diseases affecting over 140 million patients globally, including asthma and atopic dermatitis [4] Group 3: Industry Context - Asthma is a chronic inflammatory lung disease with significant unmet treatment needs despite existing therapies [5] - The ongoing development of KT-621 reflects the industry's focus on innovative oral treatments that can provide biologics-like efficacy for inflammatory diseases [4][6] - Kymera Therapeutics is positioned as a pioneer in targeted protein degradation, aiming to develop effective therapies for conditions that are difficult to treat with conventional methods [6][7]

Core Insights - Kymera Therapeutics, Inc. (NASDAQ:KYMR) is recognized as one of the 14 best booming stocks to buy, with shares increasing over 28% in the last three months and a projected further increase of nearly 60% as of January 12 [1] Group 1: Stock Performance and Analyst Ratings - The stock has seen a 28% increase over the past three months, but Wolfe Research downgraded it to Peer Perform from Outperform on January 6 and removed its $92 price target [2] - Despite the downgrade, Wolfe Research considers Kymera a good long-term investment, although it cites a lack of catalysts for short-term upside and valuation concerns [3] - BTIG has reiterated a Buy rating with a price target of $138, while Citigroup maintained its Buy rating with a target of $110 [4] Group 2: Company Developments - In December, Kymera received Fast Track designation from the FDA for its KT-621 oral STAT6 degrader aimed at treating atopic dermatitis, following positive results from the BroADen Phase 1b clinical trial [5] - The company focuses on developing protein degradation therapies to address significant medical issues [5]

Group 1 - The article discusses the importance of enabling Javascript and cookies in browsers to prevent access issues [1] - It highlights that users with ad-blockers may face restrictions when trying to access content [1]

Company Overview - Kymera Therapeutics was founded ten years ago and has focused on building strategic capabilities to develop a new generation of medicines [3] - The company aims to create oral drugs that exhibit biologics-like activity, a novel approach in the pharmaceutical industry [3] Future Outlook - Kymera plans to outline its vision for 2026 and the next 3 to 5 years during the presentation [2] - The year 2025 is highlighted as a pivotal year for the company, indicating significant upcoming developments [4]

Summary of Kymera Therapeutics FY Conference Call Company Overview - **Company**: Kymera Therapeutics (NasdaqGM:KYMR) - **Event**: FY Conference at the 44th J.P. Morgan Healthcare Conference - **Date**: January 13, 2026 - **CEO**: Nello Mainolfi Key Points Company Vision and Strategy - Kymera aims to develop a new generation of oral drugs with biologics-like activity, focusing on immunology [2][6] - The company has spent 10 years building its strategy, capabilities, and team to achieve this vision [2] Recent Achievements - 2025 was a pivotal year, with the completion of early clinical translation of KT-621, demonstrating effective degradation of STAT6 in humans [3][4] - Initiated a Phase 1 study for KT-621 and presented a new program, KT-579, targeting IRF5 [4][5] - Collaborations with Sanofi and Gilead, raising nearly $1 billion to fund operations through at least 2029 [5] Market Opportunity - Over 100 million patients in major markets suffer from immune-inflammatory diseases, but only about 5 million access advanced systemic therapies [9] - Kymera aims to transform treatment paradigms by offering oral drugs that provide the efficacy and safety of biologics [10] Product Pipeline - **KT-621**: Targeting IL-4 and IL-13 pathways, with Phase 2b studies initiated for atopic dermatitis (AD) and asthma [13][29] - **KT-579**: A new program targeting IRF5, with a Phase 1 study expected to start soon [14] - **IRAK4 Degrader (KT-485)**: Second-generation degrader in collaboration with Sanofi [5] Clinical Data and Efficacy - KT-621 showed robust reductions in biomarkers associated with type 2 inflammation, including TARC and Eotaxin, with effects comparable to or superior to existing biologics [22][23] - Demonstrated significant improvements in clinical endpoints for AD, including reductions in itch and sleeplessness [27][28] - The drug is designed to be effective regardless of the severity of the disease or prior treatment with biologics [26] Safety Profile - KT-621 has shown a compelling safety profile with no treatment-related adverse events reported in clinical studies [35] Future Plans - Kymera plans to complete enrollment for the AD study and continue the asthma study, with data expected by 2027 [39] - The company aims to initiate multiple Phase 3 studies in parallel for various indications [37] Market Dynamics - The current market for biologics targeting type 2 inflammation is valued at $20-30 billion, with Kymera aiming to expand this market by increasing patient access to effective oral therapies [19][20] Conclusion - Kymera Therapeutics is positioned to lead a transformation in the treatment of immune-inflammatory diseases through innovative oral therapies that combine the efficacy of biologics with the convenience of oral administration [7][10]